

***CURRICULUM VITAE***

Charles L. Daley, M.D.

**I. Personal Data**

Birthplace: Jackson, Mississippi  
 Present Position Rank: Professor of Medicine, National Jewish Health and University of Colorado Denver  
 Chief, Division of Mycobacterial and Respiratory Infections  
 National Jewish Health  
 Work address: Division of Mycobacterial and Respiratory Infections  
 National Jewish Health  
 1400 Jackson St., Room J204  
 Denver, CO 80206  
 (303) 398-1667  
 (303) 398-1780 (fax)  
 daleyc@njhealth.org  
 Citizenship: USA

**II. Educational and Training History****Undergraduate:**

1975-1979 University of Mississippi  
 B.A. in Zoology and Chemistry, *Summa Cum Laude*

**Medical:**

1979-1983 University of Mississippi Medical Center  
 Degree: M.D., *Summa Cum Laude*, Valedictorian

**Internship/Residency:**

1983-1986 Categorical Medical Internship/Residency  
 University of California, San Francisco  
 Lloyd H. Smith, M.D., Chairman through 1985  
 Richard K. Root, M.D., Chairman, 1985 to 1989  
 1986-1987 Chief Medical Resident  
 San Francisco General Hospital  
 Merle A. Sande, M.D., Chief of Medical Service

**Fellowship:**

1988-1989 Clinical Pulmonary and Critical Care Fellow  
 University of California, San Francisco  
 1989-1991 Pulmonary Research Fellow, San Francisco General Hospital  
 Cardiovascular Research Institute (CVRI), UCSF

**Short-Term Training**

2003 IUATLD TB Consultant Course, Cambridge, MA  
 2005 First DOTS-Plus Consultant Training Course, Riga, Latvia  
 2008 Infection Control Consultant Training Course, Gaborone, Botswana

**Licensure:**

1985-2012 California license C41907  
 2004-present Colorado license 42828

### **Board Certification:**

1988-present Board Certified, American Board of Internal Medicine  
 1990-present Board Certified, Subspecialty Board on Pulmonary Disease  
 1993-present Critical Care Certification

### **III. Professional Positions**

#### **Academic:**

1991-1995 Assistant Adjunct Professor of Medicine, UCSF, Division of Pulmonary and Critical Care Medicine, SFGH  
 1995- 1999 Assistant Clinical Professor of Medicine, UCSF,  
 1999-2004 Associate Professor of Clinical Medicine, UCSF  
 2004 (Sept 1) Professor of Medicine, National Jewish Health and University of Colorado Denver

#### **Administrative:**

1991-2004 Chief, Chest Clinic, San Francisco General Hospital  
 1993-2004 Medical Director, F. J. Curry National TB Training Center  
 2002-2004 Associate Program Director, Categorical Medicine, Research and Academic Development, UCSF  
 2004 (Sept 1) Chief, Division of Mycobacterial and Respiratory Infections, National Jewish Health

#### **Clinical:**

1987-1993 Attending Physician, Emergency Dept. SFGH  
 7/87-2004 Attending Physician, Tuberculosis Clinic, San Francisco DPH  
 7/91-2004 Attending Physician, Medical ICU, SFGH  
 7/91-2004 Attending Physician, Pulmonary Consult Service, SFGH  
 2004-present Attending Physician, Division of Mycobacterial and Respiratory Infections  
 2009-2012 Attending Physician, Denver Health TB Control Program

### **IV. Honors and Awards**

#### **Undergraduate**

1975-1979 Phi Eta Sigma, AED, Sigma Pi Sigma, Phi Kappa Phi

#### **Medical School**

1979-1983 Dean's Scholar, AOA, Alford Memorial Award, Frank Bradley Baker Memorial Award, Sandoz Award, Lange Book Award, Leathers Award, Valedictorian

#### **Awards/Nominations**

2003 Nominated for "Great People Award" at UCSF

2002	Best Doctors in San Francisco, San Francisco Magazine
2001-2007, 2010	Best Doctors in America
2008	2008 Faculty Ambassador Award, NJH
2012	Best Doctor for Executives, ColoradoBiz Magazine
2012	US News and World Report, Top Doc
2013	Top Doctors, Castle Connolly

### **Teaching Awards/Nominations**

1992-1993	Nominated for teaching award; “Outstanding Leadership in a Clinical Preceptorship”
1995	Nominated for teaching award, School of Medicine, Class of 1995.
1995-96	First Pulmonary Faculty Teaching Award
2003-04	First Michael S. Stulbarg Outstanding Teaching Award
2000, 2001, 2003	Nominated for UCSF Kaiser Teaching Award (Highest teaching award)

### **V. Professional Affiliations**

#### **Memberships:**

American Thoracic Society  
 Colorado Thoracic Society  
 International Union Against Tuberculosis and Lung Disease  
 American College Chest Physicians, Fellow

### **VI. Professional Service and Committees**

#### **Institutional and Departmental Committees**

##### National Jewish Health

2006-2007	Faculty Evaluation Sub Committee
2006-2009	Immunology Faculty Search Committee

##### University of Colorado Denver

2005-2008	Member, CFAR Internal Advisory Board
2005-2010	Advisory Board, Surgical Center for Infectious Diseases
2005-present	Interviewer, Pulmonary/CCM Fellowship Committee
2005-present	Interviewer, Infectious Diseases Fellowship Committee
2009-present	Research Advisory Committee, Global Health Institute

##### San Francisco General Hospital/Community Health Network

1986-1988	Code Blue Committee, SFGH
1987-1988	Pharmacy and Therapeutics Committee, SFGH
1992-2004	Product Evaluation Committee, SFGH
1995	Community Acquired Pneumonia Practice Guidelines Committee
1995-1997	Co-chairman, Chronic Lung Disease Education Committee, SFGH
1996-2004	Risk Management Subcommittee, SFGH
1998-2004	Community Health Network of SF, Action Group on Guidelines and Practices

1998-1999 Tuberculosis sub-committee, SFGH, co-chair  
 2002-2004 Education committee

#### University of California, San Francisco

1992-1994 Grant Reviewer, AIDS Clinical Research, UCSF  
 1993-2004 Tuberculosis Consultant, UCSF HIV Telephone Consultation Service  
 1993-2004 Pulmonary Clinical Research Committee, UCSF  
 1994-2001 Search Committees (AIDS/Onc x3, Occ. Med, ICM, Student Programs)  
 1996-2004 Categorical Internship Selection Committee, UCSF  
 2000-2004 Board Member, Clinical Practice Group, Community Health Network  
 2001-2002 Co-Chair, Clinical X Promotion Guidelines Committee, UCSF  
 2001-2004 Promotions Sub-Committee for Clinical X Series, UCSF  
 2002-2004 International Therapeutics Group – HIV  
 2003-2004 Clinical and Outcomes Research Committee

#### **Professional Organizations**

##### American Thoracic Society

1996-1998 Mycobacterial Drug Susceptibility Working Group  
 2000-2003 Writing Committee, “Treatment of Tuberculosis”  
 2000-2007 Microbiology, Tuberculosis, Pulmonary Infections Assembly Program Committee  
 2003-2004 Program Chair-elect -MTPI Assembly  
 2004-2005 Program Chair, MTPI Assembly  
 2003-present Member, Planning Committee, MTPI Assembly  
 2005-2006 Chair, Planning Committee, MTPI Assembly  
 2003-2012 Member, Executive Committee, MTPI Assembly  
 2001-2005 Writing Committee, “Tuberculosis Control in the United States”  
 2003-2007 Writing Committee, “Management of Nontuberculosis Infections”  
 2004 Member, International Conference Long Range Planning Committee  
 2007-present Member, Writing Committee, “Diagnosis of Tuberculosis”  
 2007-2008 Chair-elect, MTPI Assembly  
 2008-2010 Chair, MTPI Assembly  
 2008-2010 Member, Board of Directors, ATS  
 2009-2010 Member, ATS Board of Directors Documents Review Subcommittee  
 2010-2012 Chair, MTPI Nominating Committee  
 2010-2011 Member, ATS Nominating Committee  
 2010-2012 Member, ATS Planning Committee  
 2013-present Member, Writing Committee, “Treatment of Tuberculosis”

##### California Tuberculosis Controllers Association

1994-1998 California Tuberculosis Elimination Implementation Task Force

1997 California Tuberculosis Controllers Association (CTCA), Program Committee  
 1998-1999 President-elect, CTCA  
 1999-2000 President, CTCA  
 2000-2001 Past-President, CTCA

#### California Thoracic Society

1994-2004 Education Committee, California Thoracic Society (CTS)  
 1997-2004 Executive Committee, California Thoracic Society  
 1998 Subcommittee on OSHA TB testimony  
 1998-2004 Representative for California TB Advisory Committee  
 1999-2000 Treasurer  
 2000-2001 Secretary  
 2001-2002 President-elect  
 2002-2004 President  
 2003-2004 Past – President and Chair of Nominating Committee  
 2001-2004 Chest Disease Scientific Committee, California Medical Association

#### American Lung Association of California

1995-2004 Tuberculosis Technical Advisory Group (TAG), American Lung Assoc. of California, Chairman, 1995-1999  
 1998-1999 Chairman, Program Committee for Regional Asthma Conference. Funded by ATS  
 2001-2002 Finance Committee  
 2002-2004 Executive Committee and Board Member  
 2002-2003 Research Program Committee  
 2002-2003 Government Relations Committee

#### COPD Foundation

2006-present Chair, Steering Committee, Bronchiectasis Research Consortium  
 2007-present Member, Bronchiectasis Registry Advisory Committee

#### Other

1995 TB/HIV Focus group, California Department of Public Health

#### **Community Service**

##### San Francisco, CA

1986 San Francisco Carnival Celebration Parade, Medical Director  
 1993-1994 Walter Travel Fund Review Committee, ALA, SF

##### Denver, CO

2006-present Volunteer, Showtime on Ice

#### **National Service**

Centers for Disease Control and Prevention

1997	HIV-TB Advisory Group
2001-2005	Core Science Committee- Tuberculosis Clinical Trials Consortium (review all scientific proposals and protocols)
2001-2003	Research Agenda Committee- Tuberculosis Epidemiology Consortium (review all scientific proposals and protocols)
2002-2006	Study 27 Protocol Writing Team - Randomized controlled clinical trial evaluating the difference between 2 month culture status in smear positive tuberculosis patients randomized to moxifloxacin or ethambutol plus standard antituberculosis therapy.
2005-2008	Chair, Diagnostics Working Group, TBESC, CDC
2008	Member, Expert Panel, CDC IGRA Guidelines
2012	Chair, Special Emphasis Panel
2013-present	Member, Advisory Committee, Tuberculosis Epidemiologic Studies Consortium

Other

1994-1998	National Coalition to Eliminate Tuberculosis (NCET)
2004-2006	Observer of record, Subcommittee on Laboratory Diagnosis of Mycobacterial Infections, NCCLS
2006	Bronchiectasis Working Group, NHLBI
2009	Panel Member, FDA, Drug Susceptible Tuberculosis Workshop
2012	Panel Member, FDA Workshop, Bronchiectasis Clinical Trials

**International Service**

1994	Ad Hoc Grant Reviewer, World Health Organization (WHO)
1998-2000	Problem-based Learning TB Education Work Group, WHO
1999-2002	North American Region of IUATLD, Program Committee, Chair of Abstract Comm.
2006-2010	ATS representative, WHO DOTS-Plus Working Group
2006-2008	ATS representative, TBCAP Chest Radiograph Working Group
2007-2008	ATS representative, TBCAP MDR-TB Working Group
2007-2009	Alternate member, Green Light Committee, CDC
2009-2010	Primary member, Green Light Committee, CDC
2010-2011	Primary member, Green Light Committee, ATS
2008-present	Member, International Standards for Tuberculosis Control Steering Committee
2009-2011	Expanded Access Working Group
2010	Rapporteur, Special Session on GLC Governance
2010	Participant, Consensus Meeting on TB in Palliative Care
2010-present	Member, MDR-TB Core Group
2010-2011	Chair, Green Light Committee, ATS Representative
2011	Speaker, NCTB/WHO/IUATLD Training
2010-present	Member, STAG Committee, WHO
2011	Speaker, MDR-TB Stakeholder Meeting
2011-present	Chair, gGLC, WHO and Stop TB Partnership

**Program Reviews/Consultancies**

1993	Consultant, Tanzania TB Control Program
1999	Consultant, Tokyo Metropolitan TB Program
2001	Consultant, Quaxaca, Mexico TB Program
2002	Member, Program Review Team, Wyoming, USA
2002	Member, Program Review Team, Montana, USA
2003	Member, Program Review Team, Idaho, USA
2007	Lead Consultant, MDR-TB Program Review, Taiwan
2008	GLC DR-TB Consultant Training Course and Program Review, Consultant, GLC, Peru, Lead Consultant for Puno, Peru Review
2008	Consultant, MDR-TB Program Review, Taiwan
2009	Lead, Consultant, GLC, Kyrgyzstan
2010	Lead, Consultant, GLC, China (Heilongjiang)
2010	GLC DR-TB Consultant Training Course, Geneva
2011	Lead, Consultant, GLC, Philippines (Manila, Cebu, Mindanao)
2011	WHO Expert Meeting Steering Committee for WHO Policy on Introduction of New Drugs
2011	Lead, Consultant, WHO, China (Shandong)
2011	Co-chief facilitator, GLC DR-TB Consultant Training Course, Lesotho
2012	Lead, Consultant, WHO, China (Liaoning)

**DMC Activity**

2004-2009	Chairman, DSMB, NIAID Protocol DMID 03-135, Clinical Trial of Short Course Rifampin vs. INH for LTBI in Jail Populations
2005-2009	Chairman, DSMB, NHLBI funded study, Promoting Adherence to TB Regimens in High-Risk Youth
2006-2008	DSMB Member – DMID protocol 03-117, Effect Of Multivitamin Supplements on Immunological and Clinical Response in Childhood Tuberculosis
2008-present	Chairman, DMC, Otsuka Study 242-07-204
2008-present	Chairman, DMC, Otsuka Study 242-07-208
2009-present	Chairman, DMC, Otsuka Study 242-07-210
2011-present	Chairman, DMC, Otsuka Study 242-07-213
2009-present	Member, DMC, Sanofi-Aventis
2012-present	Member, SMC, NIAID, Protocol 11-0006
2012-present	Chair, DSMB, NIAID, Protocol 10-0061

**VII. Patents – None****VIII. Review and Referee Activities**Associate Editor

2010-present	American Journal of Respiratory and Critical Care Medicine
2012-present	Respiratory Care Reports

Editorial Board

2002-2010 American Journal of Respiratory and Critical Care Medicine

Review Services:

AIDS  
 American Journal of Medicine  
 American Journal of Public Health  
 American Journal of Respiratory and Critical Care Med  
 Annals of Internal Medicine  
 Archives of Internal Medicine  
 Chest  
 Clinical Infectious Diseases  
 Emerging Infectious Diseases  
 European Journal of Respiratory Diseases  
 International Journal of Tuberculosis and Lung Disease  
 International Journal of Infectious Diseases  
 Journal of Acquired Immune Deficiency Syndrome  
 Journal of the American Medical Association  
 Journal of Antimicrobial Chemotherapy  
 Journal of Infectious Diseases  
 Lancet  
 New England Journal of Medicine  
 Public Health Reports  
 Thorax  
 Tubercle and Lung Disease  
 Journal of Zoo and Wildlife Medicine

NIH//CDC/WHO Review

1995 Ad Hoc Grant Reviewer, WHO  
 1998 Ad Hoc Grant Reviewer, NIAID  
 2002 Ad Hoc Grant Reviewer, NIAID  
 2003 Ad Hoc Grant Reviewer, BTEP  
 2005 Chairman, Special Study Panel, Fogarty, ICIDR  
 2007-present Mid-B Review Section, NIAID, ad hoc  
 2008, 2009 PA-08-149 “NIH Support for Conferences and Scientific Meetings Applications” Review Committee  
 2009 Ad Hoc Grant Reviewer, Special Study Panel, NIAID, ICIDR  
 2011 Chair, Special Emphasis TB Panel, CDC  
 2012 NIAID Special Emphasis Panel ZAI1-MMT M (S1)

**IX. Teaching:**

A. Graduate and Medical School Lectures

1992-1995 MSIII, “Pneumonia”, 1 hour  
 1995-2004 MSIII, “Tuberculosis”, Med 110, 1 hour, 8/year  
 1993-2004 PharmIII, Clinical Pharmacy, 131, “Tuberculosis”  
 1995-2004 MSIV, Pathophysiology of Disease, 140.22, “Tuberculosis”  
 1995-97, 99-01 MSI, Epidemiology and Biostatistics, 101, “Molecular Epidemiology



1995-2001	Medical Interns, Ambulatory Core Curriculum, “Prevention of TB”
2001-2004	“Molecular Epidemiology”, Advanced Training in Clinical Research
2002-2004	MSI - “International Tuberculosis Control”
2003	Doris Duke Research Fellows - “International Health”
2007-present	Mycobacterial Infections (with Marty Voskiul) – Infectious Diseases, IDPT6004, UCHSC
2007-present	Global Epidemiology of Infectious Diseases, MICB 7704, UCHSC

#### B. Medical Student Preceptor

1995	ICM 131A
1989, 90, 92	ICM 132A

#### IC. Predoctoral Students Supervised

1995-1996	Kathy DeRiemer, MPH student, UC Berkeley
1997	Stephanie Cuthbert, Medical Student, Melbourne, Australia
1998	Ada Wong, Medical Student, University of Iowa
1998-1999	Lisa Giese, Medical Student, UCSF
2001	Chris Seaman, Undergraduate, Vassar
2002	Alon Unger, UCSF

#### D. Postdoctoral Fellows/Junior Faculty Supervised (\*co-mentored)

1995-6	Marcus Conde*, MD, Fogarty Fellow, Universidad do Federal, Rio De Janeiro, Brazil
1995-1998	Robert Jasmer*, MD, Pulmonary Fellow, Junior Faculty, UCSF
2000	Elad Ziv, MD, Medical Resident, UCSF
1999-2001	Pratima Singh, MD, MSc student, San Francisco State
1999-2002	Marcos Burgos, MD, Fogarty Fellow, Columbia/US
2000-2003	Adrian Ong, MD, Fogarty Fellow, Singapore
2001	Wee Pek, MD, Pulmonary Fellow, Singapore
2000-2002	Ivan Sabogal, MD, Fogarty Fellow, Peru
2001-2003	Ted Marras, MD, MPH, Pulmonary Fellow, Toronto University
2003	Ai Ching Kor, MD, Pulmonary Fellow Singapore
2004	Payam Nahid*, MD, MPH, Pulmonary Fellow, UCSF
2005-2007	Carlos Perez Velez, MD, ID Fellow, UCHSC
2006-2007	Shannon Kasperbauer, ID Fellow, UCHSC
2006-2008	Maxine Dexter, MD, Pulmonary Fellow, UCSHC
2007-2008	Julie Jarand, MD, Post-doc, Univ. of Calgary, Alberta
2008-2009	Brendan Clarke, MD, Pulmonary Fellow, UCSHC
2009-2011	Nick Walter*, MD, Pulmonary Fellow, UCSHC
2008-2009	Seigo Kitada, MD, Osaka, Japan
2009-2010	Won-Jung Koh, MD, Seoul, South Korea
2010-2011	Chiu-ping Kuo, MD, Taipei, Taiwan
2010	Jakko van Ingen, MD, PhD, Nymegen, Netherlands

#### E. Informal Teaching - Attending Physician

1987-1991	General Medicine wards
1987-2004	San Francisco Tuberculosis Clinic

1991-2004 Pulmonary Consult Service  
 1991-2004 Medical Intensive Care Unit

#### F. Other Teaching Activities

Approximately 5-10 lectures/year to the various housestaff (noon conferences)

1996-1998 Workshop leader for “AIDS in Africa”, Annual UCSF Student AIDS Forum  
 1990-1992 Medical Consultant, Muhimbili Medical Center, Dar es Salaam, TZ  
 1900-1992 Taught chest radiography to medical students at Muhimbili

#### **Bibliography**

##### **A. Refereed journals:**

1. Goodman PC, **Daley CL**, Minagi H. Spontaneous pneumothorax in AIDS patients with *Pneumocystis carinii* pneumonia. *AJR* 147:29-31, 1986.
2. **Daley CL**. Adjuvant therapy of bacterial meningitis: Assessment by Delphi group opinion technique. *Ped Inf Dis J*. 6:1160-1, 1987.
3. **Daley CL**, Schechter G. Tuberculosis outbreak among residents in a residential facility for HIV infected persons. *MMWR* 40:649-652, 1991.
4. Greenman RL, Schein RMH, Martin MA, Wenzel RP, Emmanuel G, et al (**Daley**). A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. *JAMA* 266:1097-1102, 1991.
5. **Daley CL**, Small PM, Schechter GF, Schoolnik GK, McAdam RA, Jacobs WR, Hopewell PC. Transmission and accelerated progression of tuberculosis in patients infected with the human immunodeficiency virus: Characterization of an outbreak using restriction fragment length polymorphism analysis. *N Engl J Med* 1992;326:321-325.
6. Janoff E, Breiman R, **Daley CL**, Hopewell P. Pneumococcal disease during HIV infection: Epidemiologic, clinical, and immunologic perspectives. *Ann Intern Med* 117:314-324, 1992.
7. **Daley CL**, Kawamura ML. The role of molecular epidemiology in contact investigations: a U.S. perspective. *Int J Tuber Lung Dis* 2003;7 (Suppl 3):S458-62.
8. **Daley CL**. Pulmonary infections in the tropics: Impact of HIV infection. *Thorax* 49:370-378, 1994.
9. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schechter GF, **Daley CL**, Schoolnik GK. The contemporary urban epidemiology of tuberculosis: A population-based study using conventional and molecular methods. *N Engl J Med* 330:1703-9, 1994.
10. **Daley CL**. Pyogenic bacterial pneumonia in the acquired immunodeficiency syndrome. *J Thorac Imaging* 6:36-42, 1991.
11. Mlika-Cabanne N, Brauner M, Mugusi F, Grenier P, **Daley C**, Mbaga I, Larouze B, Murray JF. Radiographic abnormalities in tuberculosis and risk of coexisting HIV infection: Results from Dar es Salaam, Tanzania, and scoring system. *Am J Resp Crit Care Med* 152:786-793, 1995 .
12. Opstad NL, **Daley CL**, Thurn JR, Rubins JB, Merrifield C, Hopewell PC, Janoff EN. Impact of *Streptococcus pneumoniae* bacteremia and HIV-1 infection on oral mucosal immunity. *J Infect Dis* 172:566-70, 1995.
13. Amdahl BM, Rubins JB, **Daley CL**, Gilks C, Hopewell PC, Janoff EN. Impaired natural immunity to pneumolysin in HIV-infected patients in the United States and Africa. *Am J Respir Crit Care Dis* 152:2000-4, 1995.

14. Casper C, Singh SP, Rane S, **Daley CL**, Schechter GS, Riley LW, Kreiswirth BN, Small PM. Transcontinental transmission of tuberculosis: a molecular epidemiological assessment. *Am J Pub Health* 86:551-553, 1996
15. **Daley CL**, Mugusi F, Chen L, et al. Pulmonary complications of HIV infection in Tanzania: role of bronchoscopy and bronchoalveolar lavage. *Am J Respir Crit Care Med* 154:105-110, 1996
16. Vanham G, Edmonds K, Qing L, Hom D, Toossi Z, Jones B, **Daley C**, Huebner R, Kestens L, Gigase P, Ellner J. Global immune activation in pulmonary tuberculosis: synergism with concurrent HIV infection. *Clin and Exp Immunology* 103:30-4, 1996
17. Samb B, Henzel D, **Daley CL**, et al. Methods for diagnosing tuberculosis among inpatients in eastern Africa whose sputum smears are negative. *Intern J Tuberc Lung Dis.* 1:25-30, 1997.
18. **Daley CL**, Hahn JA, Moss A, Hopewell PC, Schechter GF. Incidence of tuberculosis in injection drug users in San Francisco. *Am J Respir Crit Care Med* 157:19-22, 1998.
19. Yeh RW, Ponce de Leon A, Agasino CB, Hahn J, **Daley CL**, Hopewell PC, Small PM. Genotype stability in serial secretors of *M. tuberculosis* in San Francisco. *J Infect Dis* 1998;177:1107-11.
20. Chin DP, De Riemer K, Small PM, Ponce de Leon A, Steinhart R, Schechter GF, **Daley CL**, Moss Ar, Paz A, Jasmer RM, Agasino CB, Hopewell PC. Interaction of factors contributing to the incidence of tuberculosis in San Francisco. *Am J Respir Crit Care Med* 1998;158:1797-1803
21. DeRiemer K, **Daley CL**, Reingold AL. Preventing tuberculosis among HIV-infected persons: a survey of physicians' knowledge and practices. *Preventive Medicine* 1999;28:437-444.
22. DeRiemer K, Schechter GF, Hopewell PC, **Daley CL**. Epidemiology of tuberculosis diagnosed at death in San Francisco. *Internat J Tuberc Lung Dis* 1999;3:488-493.
23. Yeh RW, Hopewell PC, **Daley CL**. Simultaneous infection with two strains of *M. tuberculosis* identified by restriction fragment length polymorphism analysis. *Internat J Tuberc Lung Dis* 1999;3:537-539.
24. Behr MA, Warren SA, Ponce de Leon A, Salamon H, **Daley CL**, Hopewell PC, Small PM. Infectivity of AFB smear-negative tuberculosis patients in San Francisco. *Lancet* 1999;53:444-449.
25. Jasmer RM, Hahn J, Small PM, **Daley CL**, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. *Ann Intern Med* 1999;130:971-978.
26. Moss AR, Hahn JA, Tulksy JP, **Daley CL**, Small PM, Hopewell PC. Tuberculosis in the homeless: a prospective study. *Am J Respir Crit Care Med* 2000;162:460-464.
27. Jasmer RM, Snyder DC, Chin DP, Cuthbert SS, Paz EA, Hopewell PC, **Daley CL**. Twelve months of isoniazid compared to four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost effectiveness analysis. *Am J Respir Crit Care Med* 2000;162:1648-1652.
28. Conde MB, Soares SLM, Mello FQ, Rezende VM, Almeida LL, Reingold A, **Daley CL**, Kritski AL. Prospective comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis. Experience at an AIDS reference center in Rio de Janeiro, Brazil. *Am J Respir Crit Care Med* 2000;162:2238-2240.
29. Ziv E, **Daley CL**, Blower S. Early therapy for latent infection. *Am J Epidemiol* 2001;4:381-385.

30. Mazurek G, LoBue P, **Daley CL**, et al. Comparison of *QuantiFERON®-TB* with tuberculin skin testing for detecting latent *Mycobacterium tuberculosis* infections in the United States. *JAMA* 2001;286:1740-1747.
31. Pai M, McCulloch M, Reingold AL, **Daley CL**, Riley LW, Colford JM. Duration of therapy for tuberculosis in patients infected with Human Immunodeficiency Virus (Protocol for a Cochrane Review). In: *The Cochrane Library*, Issue 3, 2002.
32. Jasmer RM, Saukkonen JJ, Blumberg HM, **Daley CL**, Bernardo J, Vittinghoff E, King MD, Kawamura M, Hopewell PC. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter prospective, randomized, controlled trial. *Ann Intern Med* 2002;137:640-647.
33. Conde MB, Loivos AC, Rezende VM, Soares SLM, Mello FCQ, Reingold AL, **Daley CL**, Kritski AL. The yield of sputum induction in the diagnosis of pleural tuberculosis. *Am J Respir Crit Care Med* 2003;167(5):723-5.
34. Blumberg HM, Burman WJ, **Daley CL**, et al. Treatment of tuberculosis. *Am J Respir Crit Care Med* 2003;167:604-662.
32. Burgos M, DeReimer K, Small PM, Hopewell PC, **Daley CL**. Impact of drug-resistance on the generation of secondary cases of tuberculosis. *JID* 2003;188:1878-1884.
33. Ong A, Creasman J, Hopewell PC, Gonzalez L, Wong M, Jasmer RM, **Daley CL**. A molecular epidemiologic assessment of extrapulmonary tuberculosis in San Francisco. *CID* 2004;38: 25-31.
34. Jasmer RM., Snyder DC, Saukkonen JJ, Blumberg H, Hopewell PC, Bernardo J, King MD, Kawamura LM, **Daley CL**, for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-Course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A Cost-Effectiveness analysis based on a multicenter clinical trial. *CID* 2004; 38: 363-9.
35. Marras TK. **Daley CL**. *Mycobacterium kansasii* infection in human immunodeficiency virus infected individuals . *J of Acq Immun Def* 2004;36:883-889.
36. Ziv E, **Daley CL**, Blower S. Potential public health impact of tuberculosis vaccines. *Emerg Infect Dis* 2004;10:1529-1535.
37. Jasmer RM, Seaman C, Gonzalez LC, Kawamura LM, **Daley CL**. Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy. *Am J Respir Crit Care Med* 2004;170:561-566.
38. Marras TK, Gonzalez L, **Daley CL**. Predictors of mortality in HIV-infected patients with pulmonary *Mycobacterium kansasii*. *Am J Respir Crit Care Med* 2004;170:793-798.
39. Marras TK, Wallace RJ, Koth LL, Stulbarg MS, Cowl CT, **Daley CL**. Hypersensitivity pneumonitis reaction to *Mycobacterium avium* in household water. *Chest* 2005;127:664-671.
40. Burgos M, Gonzalez LC, Paz EA, Gournis E, Kawamura M, Schechter G, Hopewell PC, **Daley CL**. Treatment of multi-drug resistant tuberculosis in San Francisco: An outpatient-based approach. *CID* 2005;40:968-975.
41. Pai M, Gokhale K, Hoshi R, Dogra S, Shriprakash K, Mendiratta DK, Narang P, **Daley CL**, Granich RM, Mazurek GH, Reingold AL, Riley LW, Colford JM. *Mycobacterium tuberculosis* infection in health care workers in rural India: comparison of a whole-blood, interferon-gamma assay with tuberculin skin testing. *JAMA* 2005;293:1-10.
42. Ong A, Rudoy I, Creasman J, Gonzalez L, Kawamura M, **Daley CL**. Tuberculosis in health care workers - A molecular epidemiologic study. *Hosp Epid Infect Control* 2006;27:453-8.

43. Cattamanchi A, Jasmer RM, Gonzalez BA, Osmond D, Kawamura LM, **Daley CL**, Hopewell PC. A thirteen-year molecular epidemiology analysis of tuberculosis in San Francisco: time for a reappraisal of control measures? In J of TB Lung Dis 2006;10:297-304.
44. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, **Daley CL**, Catanzaro A. Factors related to response to intermittent treatment of *Mycobacterium avium* complex lung disease. Am J Respir Crit Care Med 2006; 173:1283-9.
45. Johnson JL, Hadad DJ, Boom HW, **Daley CL**, et al. Early and extended bactericidal activity of levofloxacin, gatifloxacin, and moxifloxacin in pulmonary tuberculosis. Int J of TB Lung Dis 2006;10:605-612.
46. Burman WL, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher M, Choudhri S, **Daley CL**, Munsiff S, Zhao Z, Vernon A, Chaisson R. An evaluation of the activity and tolerability of moxifloxacin during the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338.
47. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, **Daley C**...An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 2007;175:367-416.
48. Nahid P, Gonzalez L, Rudoy I, de Jong B, **Daley CL**. Treatment outcomes for HIV-related tuberculosis in San Francisco. Am J Respir Crit Care Med 2007;17:1199-1206.
49. Wu B, Huang C, Kato-Maeda M, Hopewell PC, **Daley CL**, Krensky AM, Clayberger C. Messenger RNA expression of IL-8, FOXP3, and IL-12 beta differentiates latent tuberculosis infection. J of Immunol 2007;178:3688-94.
50. DeRiemer K, Kawamura M, Hopewell PC, **Daley CL**. Quantitative impact of human immunodeficiency virus infection on tuberculosis dynamics. Am J Respir Crit Care Med 2007;176:936-944.
51. Mazurek GH, Weis SE, Moonan PK, **Daley CL**, Bernardo J, Lardizabal AA, Reves RR, Tony SR, Daniels LJ, LoBue PA. Prospective comparison of tuberculin skin test and two-whole blood interferon-gamma release assays in tuberculosis suspects. CID 2007;45:837-845.
52. Boulware DR, **Daley CL**, Merrifield C, Janoff EN. Rapid diagnosis of *Streptococcus pneumoniae* infection among HIV infected adults with urine antigen detection and C-reactive protein. J of Infect 2007;55:300-309.
53. Wu B, Huang C, Kato-Maeda M, Hopewell PC, **Daley CL**, Krensky AM, Clayberger C. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin Immunol 2007;126:202-210.
54. Cattamanchi A, Nahid P, Marras TK, Gotway MB, Lee TJ, Gonzalez LC, Morris A, Webb WR, Osmond DH, **Daley CL**. Detailed analysis of the radiographic presentation of *Mycobacterium kansasii* lung disease in HIV-infected patients. Chest 2008;133:875-880.
55. Wu B, Huang C, Kato-Maeda M, Hopewell PC, **Daley CL**, Krensky AM, Clayberger C. IL-24 modulates IFN-gamma expression in patients with tuberculosis. Immunology Letters. 2008;117:57-62.
56. Kasperbauer SH, **Daley CL**. Diagnosis and treatment of infections due to *Mycobacterium avium* complex. Semin in Respir and Crit Care Med. 2008;29:569-576.
57. Heffner JE, Holgate ST, Chung KF, Niederman MS, **Daley CL**, Jett JR, Stradling JR, Wells AU, Light RW, Tapson VF, Hansell DM, Provonost PJ, Lee YC. Road ahead to respiratory health: Experts chart future research directions. Respirology 2009;14:625-636.
58. Heffelfinger JD, Patel P, Brooks JT, Calvet H, **Daley CL**, et al. Pandemic influenzae: implications for programs controlling for HIV infection, tuberculosis, and chronic viral hepatitis. Am J Public Health 2009;Suppl2:S333-9.

59. **Daley CL**. Update on Tuberculosis, 2009. Am J Respir Crit Care Med, 2010 epub.
60. Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, Pickard CG, Robert L. RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, **Daley CL**, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK. Effects of Gender and Age of Diagnosis on Disease Progression in Long-term Cystic Fibrosis Survivors. Am J Respir Crit Care Med 2010;182:614-26.
61. **Daley CL**, Griffith DE. Pulmonary non-tuberculous mycobacterial infections. In J Tuberc Lung Dis 2010 14:665-671.
62. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K: IGRA Expert Committee: Centers for Disease Control and Prevention. MMWR Recomm Rep 2010;59:1-25.
61. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GW, **Daley CL**, Kwon OJ. Clinical Significance of Differentiation between *Mycobacterium abscessus* and *Mycobacterium massiliense*: *Mycobacterium massiliense* Lung Disease Has a Better Prognosis than *Mycobacterium abscessus* Lung Disease. Am J Respir Crit Care Med 2011;183:405-410.
63. Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, **Daley CL**. Clinical and microbiological outcomes in patients receiving treatment for *Mycobacterium abscessus* pulmonary disease. Clin Infect Dis 2011;52:565-571.
64. Morris A, Crothers K, Beck JM, Huang L and the American Thoracic Society Committee on HIV Pulmonary Disease. An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary disease. Proc AM Thorac Soc 2011;8:17-26.
65. Nahid P, Jarlsberg LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, **Daley CL**. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis 2011;11:1.
66. Falzon D, Jaramillo E, Schuemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, **Daley CL**, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Keshavjee S, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio I, Raviglione MC, Rich ML, Royce S, Rüsch-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Walson JL, Wares F, Weyer K, White RA, Zignol M. WHO Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-528.
67. Kellar KL, Gehrke J, Weis SE, Mahmutovic-Mayhew A, Davila B, Zajdowicz MJ, Scarborough R, LoBue PH, Lardizabal AA, **Daley CL**, Reves R, Bernardo J, Campbell BH, Whitworth WC, Mazurek GH. Multiple cytokines are released when blood from patients with *Mycobacterium tuberculosis* infection is stimulated with *M. tuberculosis* antigens. PLoS 2011;6:e26545.
68. van Ingen J, Totten SE, Heifets LB, Boeree M, **Daley CL**. Drug susceptibility testing and pharmacokinetics question current treatment regimens in *Mycobacterium simiae* complex disease. Intern Journal Antimicrob Agents 2012;39:173-176.
69. van Igen J, Boeree MJ, van Soolingen D, Iseman MD, Heifets LB, **Daley CL**. Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? Infect Genet Evol 2012;12:832-837.
70. van Ingen J, Koh WJ, **Daley CL**. Nontuberculous mycobacterial infections. Concise Clinical Review. Am J Respir Crit Care Med, in press.
71. Walter ND, Strong M, Belknap R, Ordway DJ, **Daley CL** Chan ED. Translating basic science insight into public health action for multidrug and extensively drug resistant tuberculosis. Respirology 2012;17:772-791.

72. van Ingen J, Levin A, Totten SE, Heifets LB, Peloquin C, **Daley CL**. Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for *Mycobacterium avium* complex disease. *Am J Respir Crit Care Med* 2012;186:559-65.
73. Shojaei H, **Daley CL**, Gitti Z, Hashemi A, Heidarich P, Moore E, Nser AD, Osterhout J, Russo C, van Ingen J, Tortoli E. *Mycobacterium iranicum* sp. Nov., a rapidly growing schotochromogenic species isolated from clinical specimens in three different continents. *Intern J System Evol Micro*. 2012. July 27, epub.
74. Choi GE, Shin SJ, Won CJ, Min KM, Oh T, Hahn MY, Lee K, Lee SH, **Daley CL**, Jeon K, Koh WJ. Macrolide treatment for *Mycobacterium abscessus* and *M. massiliense* infection and inducible resistance. *Am J Respir Crit Care Med* 2012;186:917-25.
75. Van Ingen J, Totten SE, Heifets LB, Peloquin C, Boeree MJ, **Daley CL**. In vitro synergy between clofazimine and amikacin in nontuberculous mycobacterial disease. *Antimicrob Agents Chemother* 2012;56:6324-7.
76. Collard HR, Morris A, **Daley CL**, Humbert M, Meyer KC. Clinical year in review IV: HIV, mycobacterial disease, pulmonary hypertension, and interstitial lung disease. *Proc Am Thorac Society* 2012;9:204-209.
77. Kitada S, Levin A, Hiserote M, Clark BJ, Harbeck RJ, Lichtenstein KA, Czaja CA, Huitt GA, S Kasperbauer SH, Perez-Velez CM, and **Daley CL**. Serodiagnosis of *Mycobacterium avium* complex pulmonary disease in the United States. *Europ Resp J* 2012 Oct 25 (epub ahead of print).
78. Horsburgh CR Jr, Haxaire-Theeuwes M, Lienhart C, et al. Compassionate use of and expanded access to new drugs for drug-resistant tuberculosis. *Int J Tuber Lung Dis* 2013;17:146-52.
79. Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P, Beylis N, Boeree MJ, Cacho J, Chihota V, Chimara E, Churchyard G, Cias R, Dasa R, **Daley CL**, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: a NTM-NET collaborative study. *Eur Respir J* 2013;Apr 18 epub head of press.
80. Catanzaro A, **Daley C**. Summary of 3<sup>rd</sup> global interferon-gamma release assays (IGRA) symposium. *Infection Control and Hospital Epidemiology*. 2013;34:619-24.
81. **Daley CL**, Reves RR, Beard MA, Boyle J, Clark RB, Beebe JL, Catanzaro A, et al. A summary of meeting proceedings on “Addressing variability around the cut-point in serial interferon gamma-release assay testing”. *Infection Control and Hospital Epidemiology*. 2013;34:625-30.

## **B. Manuscripts submitted**

1. Honda C, Franzini L, Graviss EA, Dorman SE, **Daley CL**, and the TBESC. Comparative costs of tuberculin skin test, interferon gamma release assays in the United States.
2. Dorman SE, Belknap R, Graviss EA, Reves R, Schluger N, Weinfurter P, Wang Y, Cronin W, Hrisch-Moverman Y, Teeter LD, Parker M, Garrett DE, **Daley CL**. Comparison of interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States.
3. Martiniano SL, Sontag MK, **Daley CL**, Nick JA, Sagel SD. Clinical significance of a first positive nontuberculous mycobacterial culture in cystic fibrosis.

## **C. Book Chapters and Reviews:**

### **Invited Reviews (non peer reviewed):**

1. **Daley CL**, Sande MA. The Runny Nose: Infection of the paranasal sinuses. *Infectious Dis Clin of N Amer.* 2:131-147, 1988.
2. **Daley CL**. Bacterial pneumonia in HIV infected patients. *Seminars in Respiratory Infection* 8:104-115, 1993.
3. Salfinger M, Hale YM, **Daley CL**. Drug-resistant tuberculosis. *RT.* 10:85-93, 1997.
4. Bradford WZ, **Daley CL**. Multidrug-resistant tuberculosis. *Infectious Disease Clinics of North America.* 1997; 157-172.
5. Marras T, **Daley CL**. Epidemiology of nontuberculous mycobacteria. *Clin Chest Med.* 2002;23:623-632.
6. Griffith D, **Daley CL**. Management of lung disease due to rapidly growing mycobacteria. *Clin Chest Med.* 2002;23: 553-567.
7. DeRiemer K, **Daley CL**. Molecular Epidemiology of Tuberculosis. *Seminars in Respiratory and Critical Care Medicine.* Ed Heifets L. 2004;25:297-306.
8. **Daley CL**. Molecular Epidemiology: a tool for understanding control of tuberculosis transmission. *Clin Chest Med.* 2005;26:217-31.
9. Nahid P, **Daley CL**. Prevention of tuberculosis in HIV infected patients. *Current Opinions in Infectious Diseases* 2006;19:189-193.
10. **Daley CL**. Treatment of *M. avium* complex pulmonary infections. *Clin Chest Med* (in press).
11. **Daley CL**. Nontuberculous mycobacterial infections in transplant patients; early diagnosis and treatment. *Curr Opin Organ Transplant.* 2009;14:619-24.
12. **Daley CL**. Mycobacterial infections. *Seminars in Respiratory and Critical Care Medicine,* 2-13;34:1.
13. **Daley CL**, Caminero J. Multidrug-resistant Tuberculosis. *Seminars in Respiratory and Critical Care Medicine,* 2013;34:44-59.

#### **Book/Monograph Chapters:**

1. **Daley CL**, Hollander H. The Acquired Immunodeficiency Syndrome. In: Skach B, Daley CL, Forsmark CE, eds, Handbook of Medical Treatment. Jones Medical Publications, 18<sup>th</sup> edition, 1988: 397-424.
2. Noble P, **Daley CL**, Brown JK. Respiratory Diseases. In: Skach B, Daley CL, Forsmark CE, eds, Handbook of Medical Treatment. Jones Medical Publications, 18<sup>th</sup> edition, 1988:78-101.
3. **Daley CL**, Sande MA. Outpatient acquired pneumonia. In: Stein JH, ed, Internal Medicine. Little, Brown, and Co, 2<sup>nd</sup> edition, 1990.
4. **Daley CL**. AIDS in Africa. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Little-Brown, 2<sup>nd</sup> ed., 1990.
5. **Daley CL**. Encapsulated bacteria in HIV infection. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Little-Brown, 2<sup>nd</sup> ed., 1990.
6. **Daley CL**. Current issues in the pathogenesis and management of tuberculosis. In Volberding PA, Jacobson MA, AIDS Clinical Review. Marcel Dekker. 1998, pg 289-321.
7. **Daley CL**. Tuberculosis. Antimicrobial Therapy and Vaccines. Ed. Nu, V. 1<sup>st</sup> ed. 1998, pg. 521-541.
8. **Daley CL**. AIDS in Africa. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Little-Brown, 3<sup>rd</sup> ed., 1997.
9. **Daley CL**. Pneumococcal disease in HIV infection. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base. Little-Brown, 3<sup>rd</sup> ed., 1997.



10. **Daley CL**, Hopewell PC. Tuberculosis. Hospital Medicine. Ed Wachter, Hollander, Goldman. 1<sup>st</sup> ed. 1999.
11. **Daley CL**. Tuberculin Skin Testing. Clinics Atlas to Office Procedures, 1999.
12. **Daley CL**. Pulmonary Tuberculosis. Kelley's Textbook of Internal Medicine. Ed Humes HD, Fourth ed. 1999.
13. **Daley CL**. Tuberculosis and HIV. In Cohen PT, Sande M, Volberding P, eds, The AIDS Knowledge Base . Internet Text. 2003
14. **Daley CL**. Latency. In Rom and Garay, 2<sup>nd</sup> ed. of Tuberculosis. 2004
15. **Daley CL**. Tuberculosis. Antimicrobial Therapy and Vaccines. Ed. Nu, V. 2<sup>nd</sup> ed. 2003
16. DeReimer K, **Daley CL**. Molecular Epidemiology of Tuberculosis in Tuberculosis Ed Madkour MM. 1<sup>st</sup> ed. 2003.
17. **Daley CL**, Gotway M, Jasmer R. Radiographic Manifestation of Tuberculosis. A primer for clinicians. 1<sup>st</sup> ed. 2003.
18. Chiang Chen-Yuan, van Cleeff M, **Daley C**, et al. Handbook for District Hospitals in Resource Constrained Settings on Quality Assurance of Chest Radiography: for better TB control and health system strengthening. Tuberculosis Coalition for Technical Assistance. July 2008.
19. **Daley CL**. Treatment of Latent Tuberculosis Infection. Yew WW in 2007.
20. **Daley CL**. Nontuberculous Mycobacterial Infections. Bacterial Infections in Humans. 4<sup>th</sup> ed., eds Brachman and Abrutyn. Springer Pub. New York, NY. 2009.
21. **Gotway M, Daley CL**. Radiographic Manifestations of Tuberculosis. Tuberculosis- a comprehensive clinical treatise. 1<sup>st</sup> ed. Zumla and Schaaf. 2009.
22. **Daley CL, Heifets L**. Nontuberculous Mycobacteria. Tuberculosis- a comprehensive clinical treatise. 1<sup>st</sup> ed. Zumla and Schaaf. 2009.
23. **Daley CL**. Tuberculosis and Nontuberculous Mycobacteria. Clinical Respiratory Medicine, 3<sup>rd</sup> ed. Eds Albert, Spiro, and Jett. Elsevier, 2008.
24. **Daley CL**. Molecular Epidemiology of Tuberculosis. 4<sup>nd</sup> ed. Tuberculosis, Davies, Barnes, and Gordon, 2008.
25. Clarke B, **Daley CL**. Nontuberculous Mycobacterial Infections. Respiratory Infections. Ed. Sethi, 2009
26. **Daley CL** and Griffith D. Nontuberculous Mycobacterial Infections. Textbook of Respiratory Medicine. Murray and Nadel 2010.
27. **Daley CL**. Nontuberculous (Environmental) Mycobacterial Disease. Breathing in American: Diseases, Progress, and Hope. Ed. Dean E. Schraufnagel. American Thoracic Society, 2010.
28. **Daley CL and Uber PA**. Anti-infective Drug Interactions, Toxicities, and Clinical Management in Cardiothoracic Transplantation for Mycobacterial Infections. Diagnosis and Management of Infectious Diseases in Cardiothoracic Transplantation and Mechanical Circulatory Support. ISHLT Monograph Series. Eds Mooney ML, Hannan MM, Husain S, Kirklin JK. 2011; Vol 5:115-125.
29. **Daley CL**. Nontuberculous mycobacteria. Bronchiectasis. European Respiratory Monograph. 2011.
30. Leung CC, Reider HL, **Daley CL**, Yew WW. Management of Adverse Reactions to Antituberculosis Drugs, ERS Monograph, in press.
31. Mauchley DC, **Daley CL**, Iseman MD, Mitchell JD. Pulmonary resection and lung transplantation for bronchiectasis. Clin Chest Med 2012;33:387-96.
32. **Daley CL**. Rapidly growing nontuberculous mycobacteria. Decision Support 2012, in press.

33. **Daley CL.** Slowly growing nontuberculous mycobacteria. Decision Support 2012, in press.
34. Kasperbauer SH, **Daley CL.** Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteria, Up To Date, Inc. Topic 85798, Version 2.0, July 2012.
35. Kasperbauer SH., **Daley CL.** Treatment of osteomyelitis due to nontuberculous mycobacteria, Up To Date, Inc. Topic 13995, Version 2.0, Nov., 2012.

#### **D. Other publications**

##### **Editorials/Commentaries/Letters:**

1. **Daley CL.** Tuberculosis recurrences in Africa: relapse or reinfection? *Lancet* 342:756-757, 1993.
2. **Daley, CL.** The typically “atypical” radiographic presentation of tuberculosis in advanced HIV disease. *Tubercle and Lung Dis* 76:475-76, 1995.
3. **Daley, CL.** Transmission of multidrug-resistant tuberculosis: Limited by man or nature? *Am J Respir Crit Care Med* 2002;165:742-743.
4. **Daley CL, Blower S.** Problems and solutions for the Stop TB Partnership. *Lancet-Infectious Diseases* 2002;2:374-6.
5. **Jasmer R, Daley CL.** Rifampin and Pyrazinamide: Is it Safe? *Am J Respir Crit Care Med* 2003;167:809-812.
6. **Daley CL.** Tuberculosis Contact Investigations: Please don’t fail me now. *Am J Respir Crit Care Med* 2004;169:779-81.
7. Mazurek GH, LoBue PA, **Daley CL,** et al. Detection of Mycobacterium tuberculosis infection by whole-blood interferon-gamma release assay (letter). *Clin Infect Dis* 2003;36:1207-1208.
8. Burgos M, DeRiemer K, Small PM, Hopewell PC, **Daley CL,** Reply. *J Infect Dis.* 2004;190:650-651.
9. Burgos M, Deriemer K, Small PM, Hopewell PC, **Daley CL.** Reply. *J Infect Dis.* 2005 1;191(5):824.
10. Winthrop K, **Daley CL,** Griffith D. Nontuberculous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy. *Nature Clin Practice Rheum* 2007;3;E1.
11. Winthrop K, **Daley CL.** A novel assay for screening patients for latent tuberculosis infection prior to anti-tumor necrosis factor therapy. *Nature Clin Practice Rheum* 2008;4:456-7.
12. van Ingen J, de Lange WC, Boeree MJ, Iseman MD, **Daley CL,** Heifets LB, Bottger EC, van Soolingen D. XDR Tuberculosis. *Lancet Infectious Disease* 2011;11:585.
13. Chang KC, Leung CC, **Daley CL.** Linezolid for MDR-TB: a potentially dangerous undertaking. *Lancet ID,* 2012;12:502-503.
14. **Daley CL,** Iseman M. *Mycobacterium avium* complex and lung cancer: chicken or egg? Both? *J Thorac Oncol* 2012;7:1329-30.
15. Winthrop KL, Weinblatt ME, **Daley CL.** You can’t always get what you want, but if you try sometimes (with two tests-TST and IGRA—for tuberculosis) you get what you need. *Ann Rheum Dis* 2012, Sept 12, epub.
16. Chang KC, Leung CC, **Daley CL.** Linezolid for multidrug-resistant tuberculosis – authors’ reply. *Lancet Infect Dis* 2013;13:16-7.

##### **Editing:**

1. Handbook of Medical Treatment. Skach B, **Daley CL**, Forsmark CE, eds. 18<sup>th</sup> ed. 1988.
2. Seminars in Respiratory Infection. Pulmonary Complications of HIV Infection. Guest Editor: **CL Daley**. June 1993.
3. Nontuberculous Mycobacteria; Clinics in Chest Medicine. **Daley CL**, Catanzaro A, eds Sept. 2002;23:529-694.
4. **Daley CL**, Gotway M, Jasmer R. Radiographic Manifestation of Tuberculosis. A primer for clinicians. 1<sup>st</sup> ed, 2003.
5. **Daley CL**, Gotway M, Jasmer R. Radiographic Manifestation of Tuberculosis. A primer for clinicians. 2<sup>nd</sup> ed, 2006.
6. Drug-resistant Tuberculosis. A Survival Guide for Clinicians. Eds. Loeffler AM, **Daley CL**, Flood JM, 1<sup>st</sup> ed, 2004.
7. Drug-resistant Tuberculosis. A Survival Guide for Clinicians. Eds. Loeffler AM, **Daley CL**, Flood JM, 2<sup>nd</sup> ed, 2008.
8. World Health Organization. Guidelines for the Programmatic Management of Drug-resistant Tuberculosis. 2008 Emergency update. Member of Reference Committee.
9. Mycobacterial infections. Guest Editor **Daley CL**. Seminars in Respiratory and Critical Care Medicine, 2013;34 ISSN 1069-3424.
10. Nontuberculous Mycobacterial Infections. Guest Editors **Daley CL**, Huitt G. Clinics in Chest Medicine, in preparation.

#### **CDROM and Internet:**

1. Tuberculosis: An interactive guide for clinicians. Medical Consultant, 1998. Award for Outstanding Course Production from California Distance Learning Health Network.
2. Featured Case, Medical Consultant, 1998-present. Interactive case on Curry National TB Centers web page ([www.nationaltbcenter.edu](http://www.nationaltbcenter.edu)).
3. TB and HIV: An Online Course for Clinicians ([www.nationaltbcenter.edu](http://www.nationaltbcenter.edu))
4. **Daley CL**, Gotway M, Jasmer R. Radiographic Manifestation of Tuberculosis. A primer for clinicians. 1<sup>st</sup> ed, in 2<sup>nd</sup> printing ([www.nationaltbcenter.edu](http://www.nationaltbcenter.edu))

#### **E. Abstracts (selected):**

1. **Daley CL**. Adjuvant therapy of bacterial meningitis: assessment by Delphi group opinion technique. Presented at a symposium on bacterial meningitis in La Costa, CA. 1988.
2. **Daley CL**, Small PM, Schechter G, et al. Characterization of an outbreak of tuberculosis using RFLP analysis. Presented at the American Federation for Clinical Research, Carmel, CA, Feb. 7, 1992.
3. **Daley CL**, Steinhart R, Reingold A, Hopewell PC. Development of a mechanism to identify preventable tuberculosis cases. Am Rev Respir Dis 145:A223, 1992.
4. **Daley CL**, Fennelly K, Stansell J, et al. Nontraumatic pneumothorax in HIV infected patients. Am Rev Respir Dis 145:A821, 1992
5. **Daley CL**, Chen L, Mugusi F, et al. Pulmonary complications of HIV infection in Tanzania. Am Rev Respir Dis 145:A821, 1992.
6. Janoff E, **Daley CL**, et al. Pneumococcal meningitis in the modern era. International Conference on Antimicrobial and Chemotherapeutic Agents, Anaheim, CA, 1992.
7. Janoff E, **Daley CL**, et al. Immunoglobulin response to pneumococcal disease in HIV infected patients. International Conference on Antimicrobial and Chemotherapeutic Agents, Anaheim, CA, 1992.

8. Janoff EN, **Daley CL**, Zhai Y, et al. Acute phase responses to *Streptococcus pneumoniae* are intact in HIV-infected patients. AAI/CIS meeting, 1993.
9. Villarino M, Geiter L, Hopewell P, **Daley C**, Rudoy I, Lyle M. Parameters of cell-mediated immunity (CMI) in tuberculosis patients with human immunodeficiency virus (HIV+) and without HIV (HIV-) coinfection. *Am Rev Respir Dis* 147:A216, 1993.
10. Mlika-Cabanne N, Brauner M, Grenia P, Kamanfu G, **Daley C**, Aubry P, Mbaga I, Murray JF. Radiographic findings in HIV-seropositive and seronegative African patients with tuberculosis and derivation of a score to predict serologic status. *Clinical Research*, Washington 1994, pp 280A.
11. Ruston DC, Small PM, Paz T, Schoolnik G, **Daley C**, Hopewell P. Investigation of a cluster of TB patients: Molecular vs conventional epidemiology. *Am Rev Respir Dis* 149:A526, 1994.
12. **Daley CL**, Rudoy I, Small PM, Schechter GF, Hopewell PC. Efficacy of a 6-month regimen in the treatment of tuberculosis in HIV infected patients. abstract #29. *Tubercle and Lung Disease* 75:8, 1994.
13. **Daley CL**, DeReimer K, Small PM, Schechter GF, Hopewell PC. Tuberculosis diagnosed at death in San Francisco. *Am J Respir Crit Care Med* 151:A147, 1995.
14. Chin DP, DeReimer K, Small PM, Schechter GF, **Daley CL**, Hopewell PM. Recent transmission and reactivation of *Mycobacterium tuberculosis* among foreign-born persons in San Francisco. *Am J Respir Crit Care Med* 151:A666, 1995.
15. **Daley CL**, Rudoy I, Schechter GF, Hopewell PC. CD4 lymphocyte count before and after treatment for tuberculosis. Presented at Lancet TB Conf. Washington, D.C., 9/95
16. **Daley CL**, Hahn J, Moss A, Schechter GF. Risk of tuberculosis in anergic injection drug users. *Tubercle and Lung Dis.* 76:137, 1995.
17. Samb B, **Daley CL**, Niyongabo T, et al. Clinical features of pulmonary tuberculosis among smear negative patients in East Africa. *Tubercle and Lung Dis.* 76:143, 1995.
18. **Daley CL**, Small PM, Ponce de Leon, et al. Tuberculosis recurrences in San Francisco: Relapse or reinfection. *Am J Respir Crit Care Med* 153:A110, 1996.
19. **Daley CL**, Bibbins-Domingo K, Ponce de Leon, et al. Laboratory cross-contamination of *M. tuberculosis* cultures: a disappearing phenomenon in San Francisco. *Am J Respir Crit Care Med* 153:A36, 1996.
20. Hahn J, Zolopa A, Tulsy J, **Daley CL**, Small P, Hopewell P, Moss A. Incidence of active tuberculosis in a population based sample of homeless persons in San Francisco. *Am J Respir Crit Care Med* 153:A132, 1996.
21. **Daley CL**, DeReimer K, Hopewell PC. Tuberculosis transmission among HIV-infected persons. *Am J Respir Crit Care Med* 155:A225, 1997.
22. Jasmer RM, Hahn J, Hopewell PC, **Daley CL**, Moss AR, Small PM. Trends of transmission of *M. tuberculosis* in San Francisco. *Am J Respir Crit Care Med* 155:A227, 1997.
23. Soares SLM, Mello FCQ, Rezende VMC, Conde MB, Pinheiro MCAC, Almeida LL, Reingold A, **Daley C**, Kritski A. Characteristics of 151 respiratory symptomatic patients suspected of having pulmonary tuberculosis in Rio de Janeiro, Brazil. *Am J Respir Crit Care Med* 157:A573, 1998.
24. Mazurek GH, LoBue PA, Lardizabal AA, Bernardo J, **Daley CL**, Bishai WR, Rothel JS. Comparison of QuantiFERON-TB and tuberculin skin testing. *The International Journal of Tuberculosis and Lung Disease*;3(Suppl 1 ); S184, 1999.

25. Jasmer RM, Snyder CD, Cuthbert S, Chin DP, Paz PC, Hopewell PC, **Daley CL**. Isoniazid compared to isoniazid and rifampin for previous tuberculosis (TB-4): An outcome and cost-effectiveness analysis. *Am J Respir Crit Care Med* 161:A253, 2000.
26. Martinez AN, Bradford WZ, Agasion CB, Paz T, **Daley CL**. Outbreak of rifampin mono-resistant (RMR) tuberculosis (TB) in San Francisco. *Am J Respir Crit Care Med* 161:A304, 2000.
27. Jasmer RM, Bernardo J, **Daley CL**, Merrifield C, Blumberg HM, Saukkonen JJ, Stringer HG, Hopewell PC. Short course rifampin and pyrazinamide versus isoniazid for latent tuberculosis infection: a multicenter, prospective, randomized, controlled trial. *Am J Respir Crit Care Med* 161:A524, 2000.
28. Creasman JM, Hopewell PC, Small PM, **Daley CL**. Cluster dynamics of *M. tuberculosis* in San Francisco. *Am J Respir Crit Care Med* 161:A896, 2000.
29. Martinez AN, **Daley CL**. Epidemiology of rifampin mono-resistant tuberculosis in San Francisco. *Am J Respir Crit Care Med* 161:A897, 2000.
30. Ong A, Creasman J, Rudoy I, **Daley CL**. Epidemiology of tuberculosis among health care workers. *Am J Respir Crit Care Med* 163:A965, 2001
31. Jasmer RM, Snyder DC, Saukkonen JJ, Blumberg HM, Bernardo J, King M, Hopewell PC, Kawamura LM, **Daley CL**. Short course rifampin and pyrazinamide versus isoniazid for latent tuberculosis infection: A Cost-effectiveness analysis based on a multicenter randomized trial.. *Am J Respir Crit Care Med*, 2002;165:A17.
32. Burgos M, DeReimer K, Small PM, Hopewell PC, **Daley CL**. Relative fitness of drug-resistant and drug-susceptible strains of *M. tuberculosis* in San Francisco. *Am J Respir Crit Care Med*, 2002;169:A18.
33. Burgos M, Paz A, Schechter G, Hopewell PC, Kawamura M, **Daley CL**. Treatment of multi-drug resistant tuberculosis. *Am J Respir Crit Care Med*, 2002;169:A715.
34. Ong A, Creasman J, Wong M, Hopewell P, **Daley CL**. Molecular epidemiology of extrapulmonary tuberculosis. *Am J Respir Crit Care Med* 2002;165:A439.
35. Marras T, Gonzalez LC, **Daley CL**. Pulmonary *Mycobacterium kansasii* infection in human immunodeficiency virus infected individuals: diagnostic criteria and treatment in predicting survival. *AJRCCM* 2003;167:A708.
36. Jasmer RM, Seaman C, Gonzalez LC, Kawamura LM, **Daley CL**. Treatment outcomes among tuberculosis patients treated by directly observed therapy compared with self-administered therapy. *AJRCCM* 2003;167:A868.
37. Berger DM, Nolan C, Reves R, **Daley CL**. Conducting a TB Program Assessment to Identifying Regionalization Opportunities. IUATLD-NAR Annual Conference, Austin, February 26-28, 2004.
38. Spradling P, Bozeman L, Metchock B, Burman W, Chaisson D, **Daley C**, Engle M, Arevalo B, Johnson J, Moser A, Choudhri S, Munsiff S, OBrien R, Vernon A, Zhao Z, and the TBTC. Fluoroquinolone resistance among pre-treatment *Mycobacterium tuberculosis* isolates in an international multicenter randomized clinical trial. Accepted for ATS, San Diego, 2005.
39. Cattamanchi A, Jasmer RM, Gonzalez BA, Osmond D, Kawamura LM, **Daley CL**, Hopewell PC. A thirteen-year molecular epidemiology analysis of tuberculosis in San Francisco: time for a reappraisal of control measures? ATS, San Diego, 2005.
40. Burman WJ, Goldberg S, Johnson J, Muzanye G, Mosher A, Engle M, Shurjeel Choudri, Munsiff S, **Daley CL**, Borisov A, Chaisson RE, Vernon A. Effect of HIV infection on the Initial Bacteriologic Response to Treatment of Pulmonary Tuberculosis. IDSA, Toronto, 2006.

41. Huitt GA, Pomerantz M, Daley CL, Worthern GS, Fulton BA. Outcome of surgical intervention in patients with rapidly growing nontuberculous mycobacterial pulmonary infection. *Am J Respir Crit Care Méd*.
42. Dexter M, Heifets L, **Daley CL**. Fluoroquinolone resistance in *M. tuberculosis*. *Am J Respir Crit Care Méd* 2007;175:A510.
43. Kasperbauer S, Heifets L. **Daley CL**. Fluoroquinolone resistance in nontuberculous mycobacteria. *Am J Respir Crit Care Méd* 2007;175:S971.
44. Kasperbauer SH, Levin AR, Dexter M, Jarand J, Mitchell JD, Huitt G, Iseman M, Pomerantz M, **Daley CL**. Long term outcomes in patients with pulmonary *Mycobacterium avium* complex disease who undergo surgical resection. *Am J Respir Crit Care Med* 2008;177:A789.
45. Dexter ME, Levin AR, Kasperbauer SH, Schwiesow JN, Peloquin CA, **Daley CL**. Achieving target serum concentrations for patients with non-tuberculous mycobacterial infections. *Am J Respir Crit Care Med* 2008;177:A789
46. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, **Daley CL**. Risk factors for mortality in HIV-infected and non-infected patients with pulmonary tuberculosis. (IUATLD Global Lung Health Conference, Nov. 8-12, 2007, Cape Town, South Africa)
47. Pérez-Vélez, CM; Moreira-Restrepo, CA; Ferro-Ramos, BE; Wilson-Totten, SE; Dang-Ta, KC; **Daley, CL**; Heifets, LB Extensively drug-resistant tuberculosis in Colombia. (North American Region, IUATLD Conference, San Diego, CA Feb 28-March 1, 2008)
48. Hernández-Ladino, NL; Pérez-Vélez, CM; Moreira-Restrepo, CA; González, LY; Cubides-Munevar AM; Casanova-Reynolds, AL; Wilches-Luna EC; Bolivar-Cuten, GA; **Daley, CL**. Operational research: the Valle-Colorado tuberculosis group. (North American Region, IUATLD Conference, San Diego, CA Feb 28-March 1, 2008).
49. Moreira-Restrepo CA, Perez-Velez CM, Gonzalez LY, Osorio-Lozano D, Casanova-Reynolds AL, Wilchest-Luna EC, Hernandez-Ladino NL, Cubides-Munevar AM, Bolivar-Cuten GA, Giraldo D, **Daley CL**. Induced sputum as an alternative specimen for the microbiologic confirmation of pulmonary tuberculosis in children from a culture that does not allow gastric aspiration. (North American Region, IUATLD Conference, San Diego, CA Feb 28-March 1, 2008)
50. Nahid P, Metcalfe J, Gonzalez LC, Slymen DJ, Osmond DH, Kawamura LM, Hopewell PC, **Daley CL**. Tuberculosis contact investigation among drug users and homeless persons in San Francisco. *Am J Respir Crit Care Med* 2008;177:A581.
51. Dorman S, Belknap R, Weinfurter P, Teeter L, Thomas J, **Daley C**. Evaluation of new interferon-gamma release assays in the diagnosis of latent tuberculosis infection in US health care workers: Baseline results. *Am J Respir Crit Care Med* 2009.
52. Jarand JM, Levin A, Zhang L, Huitt G, Mitchell J, **Daley CL**. Clinical and microbiological outcomes in patients receiving treatment for *Mycobacterium abscessus* pulmonary disease. *Am J Respir Crit Care Med* 2009.
53. Belknap R, Kelaher J, Wall K, **Daley C**, Schluger N, Reves R. Diagnosis of latent tuberculosis infection in US health care workers: Reproducibility, repeatability and 6 month follow-up with interferon gamma release assays. *Am J Respir Crit Care Med* 2009.
54. Clark BJ, Dexter M, Levin A, Boyne ME, Harbeck R, **Daley CL**. Detection of latent tuberculosis infection in patients with end stage renal disease: interferon gamma release assays versus tuberculin skin test. *Am J Respir Crit Care Med* 2009.

55. Sheu LC, Jarlsberg L, **Daley CL**, Marras TK, Nahid PM. Epidemiology of nontuberculous mycobacterial infections at San Francisco General Hospital, ATS, May 2010.
56. Kitada S, Levin A, Hiserote M, Clark BJ, Harbeck RJ, Lichtenstein KA, Czaja CA, Huitt GA, S Kasperbauer SH, Perez-Velez CM, and **Daley CL**. Serodiagnosis of *Mycobacterium avium* complex pulmonary disease in the United States. ATS, May 2010.
57. Belknap R for the TBESC. Interferon-gamma release assays in the serial testing for latent tuberculosis infection in U.S. healthcare workers. ATS, May 2010.
58. O'Donnell A, Prevots DR, Olivier KN, LaVange L, Thomashow B, Knowles MR, **Daley CL**, Aksamit T for the Bronchiectasis Research Consortium. The Bronchiectasis Research Registry: Clinical, Microbiologic, and Treatment Characteristics. ATS, May 2010.
59. Mase S, Jereb J, **Daley CL**, Fred D, Loeffler A, Bamrah S Brostrom R, Peloquin C. The pharmacokinetics of moxifloxacin in MDR-TB cases and contacts, Federated States of Micronesia, ATS, Denver, Colorado. May 2011
60. Mase S, Jereb J, **Daley CL**, Fred D, Loeffler A, Bamrah S Brostrom R, Peloquin C. The pharmacokinetics of levofloxacin in pediatric MDR-TB cases and contacts, Federated States of Micronesia, ATS, Denver, Colorado. May 2011
61. Van Ingen J, Levin A, Totten S, Heifets LB, Peloquin C, **Daley CL**. Pharmacokinetics and drug susceptibility testing imply limited activity of current regimens for *Mycobacterium avium* complex disease. ATS, Denver, Colorado. May 2011.
62. Van Ingen J, Totten S, Helstrom NK, Heifets LB, **Daley CL**. Clofazimine and amikacin act synergistically, in vitro, against *Mycobacterium abscessus*, *Mycobacterium chelonae*, and *Mycobacterium avium* complex. ATS, Denver, Colorado. May 2011.
63. Czaja CA, Levin A, Newell JD, **Daley CL**, Cott GR. Baseline disease severity and quality of life measurements among subjects with *Mycobacterium abscessus* chronic pneumonia enrolled in a prospective cohort study of treatment response. ATS, Denver, Colorado. May 2011.
64. Van Ingen J, Totten S, Heifets LB, Peloquin C, **Daley CL**. Drug susceptibility testing and pharmacokinetics question current treatment regimens for *Mycobacterium simiae* complex disease. ATS, Denver, Colorado. May 2011.
65. Czaja CA, Levin AR, Silveira LJ, Murphy JR, **Daley CL**. Prevalence of individual and multiple antibiotic class resistance among persons with non-cystic fibrosis bronchiectasis and *Pseudomonas aeruginosa* infection. ATS, Denver, Colorado. May 2011.
66. Czaja CA, Stewart D, Levin AR, Aksamit TR, LaVange L, O'Donnell AE, Knowles MR, Thomashow B, **Daley CL**. Prevalence and clinical significance of mucoid *Pseudomonas aeruginosa* infection in adults with non-cystic fibrosis bronchiectasis: results from the bronchiectasis research registry. ATS, Denver, Colorado. May 2011.
67. Stewart D, LaVange L, Thomashow B, **Daley C**, Knowles M, Olivier K, O'Donnell A, Aksamit T for the Bronchiectasis Research Consortium. ATS, Denver, Colorado. May 2011.
68. Belknap R, Parker M, Wang Y, Dorman S, Graviss E, Weinfurter P, **Daley C** and Reves R for the TB Epidemiologic Studies Consortium. Re-running Quanti-FERON TB Gold In Tube samples as a strategy for identifying false positive results. ATS, Denver, Colorado. May 2011.
69. Walter ND, Davis JL, Dolganov G, Strong M, Andama AO, Meadows CA, den Boon S, Worodria A, Cattamanchi A, **Daley CL**, Huang L, Schoolnik GK, Geraci MW. Interactions between host and pathogen gene expression among Ugandan patients with pulmonary tuberculosis. ATS, Denver, Colorado. May 2011.

70. Merkel P, Czaja C, Alam R, **Daley C**, Nagabhushanam V. A Case of anti-interferon gamma antibodies contributing to chronic extra-pulmonary nontuberculous mycobacterial disease. Primary Immune Deficiency Disease North American Conference. Chicago, IL May 2012.
71. Aksamit TR, Carretta B, **Daley CL**, et al. The Bronchiectasis Research Registry; A collaborative research cohort for non-cystic fibrosis bronchiectasis. ATS, San Francisco, CA, 2012.
72. Mase SR, Jereb J, Martin F, **Daley CL**, et al. Pharmacokinetic Studies of Levofloxacin in children treatment for, or exposed to, multidrug-resistant tuberculosis-US affiliated Pacific Islands, 2010-2011. ATS, San Francisco, CA 2012.
73. Winthrop KL, Aksamit TR, Olivier KN, Czaja C, Metersky ML, O'Donnell AE, Thomashow B, Knowles MR, Barker AF, Tino G, Eden E, Salathe M, Schraufnagel DE, Johnson M, Leventhal J, Griffith DE, Marquis A, **Daley CL**. The respiratory microbiology of patients with nontuberculous mycobacteria from the United States Bronchiectasis Research Registry. ATS, Philadelphia, PA 2013.
74. Winthrop KL, Ku JH, Marras TK, Griffith DE, **Daley CL**, Olivier KN, Aksamit TR, Ray K, Prevots DR. Linezolid in the treatment of nontuberculous mycobacterial disease. ATS, Philadelphia, PA 2013.
75. Metersky ML, O'Donnell AE, **Daley CL**, Czaja C, Aksamit TR, Tomashow MA, Knowles MR, Griffith DE, Olivier KN, Barker AF, Winthrop KL, Tino G, Eden E, Salathe M, Schraufnagel DE, Johnson M, Leventhal J. Staphylococcus aureus in patients with non-CF bronchiectasis: results from the Bronchiectasis Research Registry. ATS, Philadelphia, PA 2013.

## **XII. Invited Lectures (selected)**

1. "Tuberculosis", Advances in Infectious Diseases, San Francisco, May, 1991.
2. "Tuberculosis: Drug Interactions in HIV-infected Patients", California Tuberculosis Controllers Association, Stockton, CA, May, 1991.
3. "Outbreak of Tuberculosis in HIV-infected Patients". Grand Rounds, San Francisco General Hospital, January, 1992.
4. "Pleural and Pulmonary Tuberculosis", Department of Corrections Infectious Disease Symposium, Sacramento, CA, January 1992.
5. "Tuberculosis in the 1990's: New Challenges". Advances in Infectious Diseases, San Francisco, May 1992.
6. "Tuberculosis in the 1990's. Advances in Internal Medicine, San Francisco, May 1992.
7. "Nosocomial Pneumonia". Surgery Grand Rounds, UCSF, June 1992.
8. "Tuberculosis". Infectious Diseases Grand Rounds, UCSF, June 1992.
9. "Tuberculosis: New Challenges". Medical Grand Rounds, Kaiser Hospital, San Rafael, August 1992.
10. "Tuberculosis: Challenges for Human Medicine". Plenary session for World Veterinarianry Congress on Infectious Diseases, Univ. of California, Davis, September 1992.
11. "Tuberculosis: Current Research". Association of Infection Control Practitioners. San Bernadino, CA, October 1992.
12. "Tuberculosis and HIV infection: Treatment and Prevention". AIDS Program, Albany Medical Center, Albany, New York, December 1992.
13. "Multidrug-resistant Tuberculosis". San Jose Medical Center Grand Rounds. San Jose, CA, December 1992.
14. "Tuberculosis and HIV infection". Riverside County Health Department. January 1993.



15. "Multidrug-resistant Tuberculosis". Respiratory Infections for the Practicing Physician. Wichita, Kansas, March 1993.
16. "Tuberculosis in the 1990's" and "Molecular Epidemiology of Tuberculosis". Stringer Lecturer, American Lung Association, Michigan, April 1993.
17. "Tuberculosis and HIV infection". Sunrise Seminar, American Thoracic Society, San Francisco, May 1993.
18. "Tuberculosis—Why Prevention?". Keynote address at the California Tuberculosis Controllers Meeting, San Jose, CA, May 1993.
19. "Tuberculosis: Epidemiology and Treatment". Advances in Internal Medicine, San Francisco, June 1993.
20. "HIV and Tuberculosis". American Lung Association, Pebble Beach, CA, November 1993.
21. "Molecular Epidemiology of Tuberculosis". Meet the Professor Seminar, American Thoracic Society, Boston, May 1994.
22. "Tuberculosis: Causes and Cures for the Epidemic". Advances in Pulmonary and Critical Care Medicine, San Francisco, October 1994.
23. "Tuberculosis and HIV-Infection", Medical Grand Rounds, SFGH, 1995
24. "Tuberculosis and HIV-Infection", Plenary Session, American College of Veterinary Pathologists, Atlanta, November 16, 1995.
25. "Tuberculosis, New Challenges from an Old Disease", Advances in Pulmonary and Critical Care Medicine, UCSF, 1993-1997.
26. "Multidrug Resistant Tuberculosis", Epidemiology and Prevention of Infectious Diseases, UCSF, 1993-1996
27. "Update on Tuberculosis", American Assoc. of Academic Anesthesiologists, Boston, May, 1996.
28. "Current Issues in the Pathogenesis and Management of HIV-related Tuberculosis", Fort Miley VAH, San Francisco, Feb. 1997.
29. "Does Molecular Epidemiology Have a Message for Global TB Control?", International Union Against Tuberculosis and Lung Disease, Chicago, IL, March, 1997
30. "Molecular Epidemiology of Tuberculosis", Keynote address, 3rd European Workshop on Tuberculosis Control. Netherlands, June 27th, 1997.
31. "Tuberculosis and HIV". Plenary Session. California Tuberculosis Controllers Association. October 1997.
32. "Community Acquired Pneumonia" and "Tuberculosis", Peruvian Medical Association, Lima, Peru, 1997
33. "The Clinician/Laboratory Interface". National Laboratory Training Network Symposia. Miami, Tampa, Jacksonville, Orlando, Anchorage. 1998, 2001
34. "Molecular Epidemiology-Lessons for TB Control". International Congress of Pediatrics. Amsterdam, Netherlands, August 1998.
35. Prevention of Tuberculosis. Moving from TB Control to Elimination. Medicine Grand Rounds, UCSF, Feb 3, 2000
36. "HIV and TB", Tokyo University, Tokyo, Japan, Feb 2000
37. "Molecular Epidemiology of Tuberculosis in San Francisco, Public Health Research Institute, Osaka, Japan, Feb, 2000
38. "Molecular Epidemiology of Tuberculosis", American Thoracic Society, Toronto, May 2000
39. TB and HIV, Oaxaca, Mexico, 2000
40. "Global Epidemiology of Tuberculosis", Edmonton, Canada, March 21, 2001.
41. "Multidrug -Resistant Tuberculosis" - INER, Mexico City, March 19, 2002.

42. "Treatment of Tuberculosis" Rio de Janeiro, Brazil, March 26, 2002.
43. "Management of Drug Resistant Tuberculosis" Oaxtepec, Mx, Sept. 25, 2002.
44. " Delivering Treatment of Latent Infection to the Foreign-born" and " Identifying Latent TB Infection" World Conference on Lung Health, Montreal, Canada, Oct. 6-10, 2002.
45. "Lung Disease Update", American Lung Association of California, San Diego, CA Oct, 2002.
46. "Treatment of Tuberculosis, A US Perspective. HIV, STD Training Program. Phoenix, AZ 2002.
47. "International Implications of Tuberculosis. Unidos. Los Cruces, NM, Nov. 21, 2002.
48. "Treatment of multidrug resistance tuberculosis. An international approach. Oaxaca, Mexico, May 2-5, 2003.
49. "Global Tuberculosis Control", Emerging Infectious Diseases, June 20, 2003, San Francisco
50. "Target Practice" and "Global Tuberculosis Control", Northern Rockies Lung Association, Big Sky, Montana, March 14-16, 2003.
51. "Treatment of MDR-TB", Binational Tuberculosis Intensive, South Padre Island, TX, October 2003.
52. "New Tuberculosis Treatment Guidelines", Four Corner's Tuberculosis Controllers Association, Durango, California, October 28-29, 2003.
53. "Pulmonary Diseases". UCSF Internal Medicine Board Recertification Course. October, 2003.
54. "Latent Tuberculosis Infection". Public Health and Tuberculosis Conference, Anchorage, Alaska, February 19-21, 2004.
55. "Clinical and Radiographic Presentation of Tuberculosis". Annual Internal Medicine Society Conference, Jaurez, MX, March 2004.
56. "Multidrug-resistant tuberculosis". INER, Mexico City, March 24, 2004.
57. "The Challenges of Multidrug-resistant Tuberculosis". 79<sup>th</sup> Annual Meeting of the Japanese Tuberculosis Society, Nagoya, Japan, April 2004.
58. "Tuberculosis: Important Issues for the Respiratory Care Practitioner". Selected Topics in Intensive Respiratory Care. April 30, 2004. San Francisco.
59. "Atypical Mycobacteria" - Clinician's Center at ATS Meeting in Orlando, 2004.
60. "Treatment of Tuberculosis" – Utah Annual Tuberculosis Conference, 2004, 2005.
61. "New Tests for Latent Tuberculosis Infection". Oaxaca, MX, June, 2005.
62. "Advances in the Diagnosis and Treatment of Latent Tuberculosis Infection". 7<sup>th</sup> Seminar on Evidence-Based Infection Control. Tokyo, Japan, July, 2005
63. "Treatment of Tuberculosis Using the New CDC and WHO Hybrid Model", Tuberculosis Control in the Pacific Islands. Honolulu, Hawaii, Dec. 1-2, 2005.
64. "Regionalizing TB Control in Low Incidence Areas", Michigan Annual Tuberculosis Conference. Lansing, MI, Nov. 29, 2005.
65. "Advances in the Diagnosis and Treatment of Tuberculosis and Latent Infection", Spanish Pulmonary Society, Madrid Spain, March 1-3, 2006.
66. "Molecular Epidemiology of Tuberculosis". AG Holley Tuberculosis Hospital. Lantana, Florida, October 26, 2006.
67. "A New Global Plan to Control TB". Illinois Council on Tuberculosis. Peoria, IL, September 13, 2006.
68. "Tuberculosis in the Foreign-born". IDSA. Toronto, Canada, October 1, 2006.
69. "Management of Nontuberculous Mycobacterial Infections" IDSA. Toronto, Canada, October 14, 2006.

70. "Advances in the Diagnosis and Treatment of Latent TB Infection", Four Corners TB Conference, October 24, 2006.
71. "Advances in the Diagnosis and Treatment of Latent TB Infection", Keystone Conference, December 16, 2006.
72. "Epidemiology of Multidrug-resistant Tuberculosis" and "Management of Multidrug-resistant Tuberculosis". World TB Day, Dublin, Ireland, March 22, 2007.
73. "Management of Nontuberculous Mycobacterial Infections". Nymegen, Netherlands. September 2007.
74. "Gamma Interferon Release Assays; Is it time to replace the TST? Four Corners TB Conference. Durango, CO. October 2007
75. "Treatment and Clinical Outcomes of MDR/XDR-TB". IUATLD Global Lung Health Conference. Cape Town, South Africa, November 2007.
76. "Infection Control in the Era of MDR/XDR-TB: Duty to Care" International Nurses Council. Cape Town, South Africa, November 2007.
77. "Advances in the Diagnosis and Treatment of Tuberculosis" Taiwan, November 2007.
78. "Tuberculosis – its still here", National Jewish Keystone Course, Keystone, CO Feb. 7, 2008
79. "Treatment of MDR/XDR-TB", Ixtapa, MX, Mexican Thoracic Society, March 28, 2008
80. "HIV and Tuberculosis. ATS, HIV Workshop, Toronto, Ontario, May 2008
81. "Treatment of MDR/XDR-TB", ATS, Toronto, Ontario, May 2008
82. "Controversies in the Management of NTM", ATS, Toronto, Ontario May 2008
83. "Tuberculosis", Post Graduate Course, ATS, Toronto, Ontario, May 2008
84. "Multidrug-resistant Tuberculosis" Webinar, American College of Pathology, June 25, 2008
85. "Diagnosis of Tuberculosis in the 21<sup>st</sup> Century". Association of Medical Laboratory Immunologists, Seattle, WA, July 10, 2008.
86. "Management of Multidrug-Resistant Tuberculosis" and "Radiographic Presentation of Tuberculosis", Illinois Council on Tuberculosis Annual Meeting, August, 2008
87. "Management of Multidrug-Resistant Tuberculosis" and "Advances in the Diagnosis and Treatment of Latent TB Infection", XV Curso Internacional de Avances en Neumología y Cuidados Intensivos. Lima, Peru, August 2008.
88. "Management of Nontuberculous Mycobacterial Infections", University of Washington Grand Rounds, September, 2008.
89. "Management of Multidrug-resistant Tuberculosis", University of New Mexico Grand Rounds, September 2008.
90. "Management of Multidrug-resistant Tuberculosis" and "Tuberculosis Infection Control", 25<sup>th</sup> Annual Tuberculosis Conference, Istanbul, Turkey, September 2008.
91. "Diagnosing and Treating Latent TB Infection" and "Medical Management of TB", Timely Topics in TB, Bozeman, MT, September 8, 2008.
92. "Chest radiographs for Diagnosing Tuberculosis: specificity and accuracy", International Union Against Tuberculosis and Lung Disease, Global Lung Health Meeting, Paris, France, October 2008
93. "Cross-resistance of Antituberculosis Drugs", Global Lung Health Meeting, Paris, France, October 2008
94. "Fundamentals in the Management of MDR-TB" and "Drug-resistant TB and HIV", 3<sup>rd</sup> MDR-TB consultants course, Lima, Peru, December 1-5, 2008.
95. "Management of XDR-TB", ATS, San Diego, May 2009
96. "Surgery for NTM Infections" ATS, San Diego, May 2009
97. "Management of Contacts to MDR/XDR-TB Patients", ATS, San Diego, May 2009

98. “Serial Testing of HCWs with IGRAs”, IGRA Conference, Dubrovnik, Croatia, May 31, 2009
99. “Management of Nontuberculous Mycobacterial Infections”, Japanese Respiratory Society, Tokyo, Japan, June 14, 2009.
100. “Management of Nontuberculous Mycobacteria and Drug-resistant Tuberculosis”. San Diego, CA, Chest 2009.
101. “Management of NTM infections in Patients with Bronchiectasis”, San Diego, CA, Chest 2009
102. “Management of MDR-TB”, CDC Panel Physician Training, New Delhi, India, January 15, 2010.
103. “Management of NTM in Patients with Cystic Fibrosis”, 10<sup>th</sup> Annual Irish Cystic Fibrosis Conference, Killarney, Ireland, February 5-6, 2010.
104. “Management of NTM Infections. NTM Symposium. Cambridge University, Cambridge, England. February 8<sup>th</sup>, 2010.
105. “Treatment of Tuberculosis”, Tuberculosis Intensive, FJ Curry National TB Center, February 23, 2010.
106. “Management of MDR-TB” – MDR-TB Consultant Training Course, Lima, Peru, March, 2010.
107. “Management of MDR-TB”, CDC Panel Physician Training, Santo Domingo, Dominican Republic, May, 2010.
108. “MDR and XDR-TB. Challenges in Management of Pulmonary Infections. American Thoracic Society Post-Graduate Course, May 15, 2010.
109. “Management of Adverse Reactions in Patients with Drug-Resistant Tuberculosis”, Beijing, China, January, 2011.
110. “Update in the Diagnosis and Treatment of NTM Infections”, California Thoracic Society Annual Meeting, Carmel, CA, January 29-30, 2011.
111. “Multidrug-resistant Tuberculosis”, “HIV and TB”, and “Nontuberculous Mycobacteria”. Chilean Thoracic Society, Santa Cruz, Chile, April 1-2, 2011.
112. “The Laboratory and Drug-Resistant Tuberculosis” and “Nontuberculous Mycobacteria”. Mexican Thoracic Society, Puebla, Mexico. April 26-28, 2011.
113. “Nontuberculous mycobacterial infections” and “IGRAs in Health Care Workers”, American Thoracic Society Meeting, Denver, CO, May 15-19, 2011.
114. “Management of Multidrug-resistant Tuberculosis”, “Infection Control”, Surgery for MDR-TB”, Novosibirsk TB Research Institute, Novosibirsk, Russia, June 12-16, 2011.
115. “Nontuberculous Mycobacterial Infections”, Bronchiectasis Symposium, London, England, September 13, 2011.
116. “Serial IGRA Testing of Health Care Workers” 3<sup>rd</sup> Global IGRA Symposium, Kona Hawaii, January 12-14, 2012.
117. “Strategies to Control Drug-resistant Tuberculosis. Global Health Lecture, University of Colorado Denver, April 14, 2012.
118. “Showers, Women, And NTM”. University of Illinois, April 19<sup>th</sup>, 2012.
119. “Treatment of Nontuberculous Mycobacteria”, “Update Rapid Grower Treatment”, “NTM Case 3. How Do I Treat My Patient with *M. abscessus*”, “Testing Effective Treatment”, “Pulmonary Infection in a Tracheostomy and Ventilator-Dependent Child”, “Mycobacterial Infections” for Clinical Year in Review. American Thoracic Society Meeting, San Francisco, CA, May 18-23, 2012.

120. “Infection Control and Health Care Worker Safety”, Nontuberculous Mycobacterial Infections in HIV infected and uninfected Patients”, South African Thoracic Society, Sun City, South Africa, August 28 to September 2, 2012.
121. “Clinical Year in Review, Tuberculosis”, European Respiratory Society, Vienna, Austria, September 2-5, 2012.
122. “Management of MDR-TB”, “Management of Adverse Reactions”, “Surgery and MDR-TB”, “XDR-TB and Palliative Care”. Vietnam NTP MDR-TB Training, September 24-26, 2012. Ho Chi Minh City, Vietnam.
123. “Update in Nontuberculous Mycobacteria” Chest Meeting, October 22, 2012, Atlanta, GA.
124. “Women, Showers, and Nontuberculous Mycobacteria”, Grand Rounds, Medical University of South Carolina, December 6<sup>th</sup>, 2012.
125. “Interferon-gamma release assays”, Medical University of South Carolina, December 5<sup>th</sup>, 2012.
126. “Nontuberculous Mycobacterial Infections”, British Thoracic Society, December 8, 2012, London, England.

**Television and Radio** (not including brief radio or television interviews)

1. “Scientific Basis of Tuberculosis”, one of four panel members in a three part satellite series taped at KQED and funded by the CDC, 1995.
2. “Tuberculosis and HIV”, one hour radio interview on Taylor Satellite Talk network, 1996.
3. “Tuberculosis 2000”, satellite broadcast from KQED, Jan 30, 1996.
4. “Whooping Cough”, Channel 2, Denver, CO, 2004, 2005
5. “XDR-TB”, World News Tonight, The Today Show, CNN, Good Morning America, etc.